Abstract: Objective The aim of this study was to investigate the virological response to direct antiviral agents (DAA),erbavir/gragrevir treatment in patients with chronic hepatitis C (CHC). Methods 82 patients with CHC were recruited in this study between March 2017 and March 2018,and were randomly divided into control (n=41) and observation group (n=41). The patients in the control group were treated with peginterferon-α and ribavirin combination,and those in the observation group were given erbavir/gragrevir. The regimen in the two groups lasted for 24 weeks. Serum HCV RNA was detected by RT-PCR,and virologic genotypes were determined by direct sequencing. The efficacy was assessed by early virological response (EVR),end-of-treatment response (ETVR) and sustained virological response (SVR). Results At the end of the treatment,serum alanine aminotransaminase level in the observation group was (47.9±19.7)U/L,much lower than 【(63.5±21.2)U/L,P<0.05】, serum aspartate transaminase level was (55.5±22.3)U/L,significantly lower than 【(81.3±25.8)U/L,P<0.05】 in the control group; the EVR,ETVR and SVR in the DAA-treated group were 48.8%,63.4% and 70.7%,not significantly different as compared to 41.5%,53.7% and 65.8% in interferon-α-treated group (P>0.05); the EVR,ETVR and SVR in 18 patients with non-HCV genotypeⅠ infection receiving DAA were 88.9%,94.4% and 88.9%,significantly higher than 52.2%,60.9% and 52.2% ( P<0.05) in 23 patients with HCV typeⅠ infection,while they were not significantly different compared to 86.7%,93.3% and 73.3% in 15 patients receiving interferon-α treatment (P>0.05); the SVR₁₂ in DAA-treated patients was 87.8%(36/41),significantly higher than 73.2%(30/41,P<0.05) in patients receiving interferon-α treatment. Conclusion The elbavir/gragrevir,a new DAAs,administration in the treatment of patients with CHC have a good short-term efficacy,which warrants further multi-centre,randomized,and control study.

Key words: Hepatitis C, Direct antiviral agents, Erbavir/gravivir, Virological response, Therapy